Bayer Bids To Be A Winner In Cell & Gene Therapy
Adopts Four-Pillar Strategy
Executive Summary
The last six weeks have seen the acquisition of AskBio, the launch of a dedicated cell and gene therapy unit and a CAR-T pact with Atara. Bayer is taking the space very seriously.
You may also be interested in...
Bayer Confident CureVac COVID Pact Will Be A Success
CEO Werner Baumann admits he was skeptical at first as to whether the German group had the necessary know-how to manufacture vaccines but the firm's expertise in the development of biotech products has strengthened his belief Bayer can deliver.
Senti Bio Raises $105m Series B Round For CAR-NKs, Led By Leaps For Bayer
The investment is the latest in Bayer’s series of moves into cell and gene therapy, amid growing industry interest in CAR-NKs.
Deal Watch: Merck & Co. Looks To Advance NASH Ambitions With Aligos
Newly public Aligos will team with Merck & Co. on oligonucleotide therapies for NASH. Maze Therapeutics launches ophthalmology and CV-focused spinouts with Alloy and BridgeBio.
Need a specific report? 1000+ reports available
Buy Reports